The Fuzzy Connection between SARS-CoV-2 Infection and Loss of Renal Function

Lakkakula, Bhaskar Vks; Roshan, Bijan; Nasri, Hamid

doi:10.1159/000508087

Cited by 4 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coronavirus 2 (SARS-CoV-2) is the virus responsible for the global epidemic that continues to infect millions of people worldwide [1][2][3][4]. SARS-CoV-2 is the seventh coronavirus identified as a human pathogen.…”

Section: Introductionmentioning

confidence: 99%

Predicting Transmissibility-Increasing Coronavirus (SARS-CoV-2) Mutations

Çalışkan,

Işık,

Kuru

et al. 2024

COVID

View full text Add to dashboard Cite

Advantageous variants of the SARS-CoV-2 virus have arisen through mutations, particularly on a single amino acid basis. These point mutations can cause changes in the structure of SARS-CoV-2 and affect the efficiency of interaction with the ACE2 protein. N501Y and E484K mutations affecting binding by ACE2 have been widely observed. This study aimed to predict SARS-CoV-2 mutations that could be as effective as N501Y and E484K and pose a danger due to their high contagiousness. Experimental data on SARS-CoV-2 and ACE2 binding and stability were associated with different amino acid properties and integrated into machine learning and computational biology techniques. As a result of the analyses made in algorithms, N501M, Q414A, N354K, Q498H and N460K have been predicted to be likely to have a dangerous effect. The N501W mutations are most likely to have dangerous effects on the spread of the coronavirus. We suggest that attention should be paid to the position 501 mutation since this position is repeated in the lists of mutations that the algorithm detected as dangerous. G446, G447, Y505, T500, Q493, Y473, and G476 were determined as the positions where dangerous variants could be seen as a result of the analyses of the multiple interaction data created with the ACE2 and RBD interaction data. The 13 dangerous positions and mutations have been detected to accurately describe the position of the mutations caused by the Omicron variant and were among the known dangerous mutations similar to those occurring at Q498, G446, Y505 and Q493 positions.

show abstract

Section: Introductionmentioning

confidence: 99%

Predicting Transmissibility-Increasing Coronavirus (SARS-CoV-2) Mutations

Çalışkan,

Işık,

Kuru

et al. 2024

COVID

View full text Add to dashboard Cite

show abstract

“…Coronavirus disease (COVID-19) is an extreme acute respiratory syndrome with the most common symptoms of moderate infection include fever, dry cough, tiredness, sore throat or dyspnea. Patients infected with this virus suffer from other potential damage to vital organs, such as gastrointestinal, cardiac, renal, and nervous systems (Gavriatopoulou et al 2020 ; Merad and Martin 2020 ; Rohollah et al 2020 ; Bhaskar et al 2020 ). Recent knowledge indicated that the SARS-CoV-2 transmission rate is higher than SRAS-CoV due to the protein structure's genetic makeup.…”

Section: Introductionmentioning

confidence: 99%

Molecular mechanism, diagnosis, and potential treatment for novel coronavirus (COVID-19): a current literature review and perspective

et al. 2021

View full text Add to dashboard Cite

Novel coronavirus disease 2019 (COVID-19) is a positive-sense single-stranded RNA virus which belongs to the Coronaviridae family. COVID-19 outbreak became evident after the severe acute respiratory syndrome coronavirus and the Middle East respiratory syndrome coronavirus in the twenty-first century as the start of the third deadly coronavirus. Currently, research is at an early stage, and the exact etiological dimensions of COVID-19 are unknown. Several candidate drugs and plasma therapy have been considered and evaluated for the treatment of severe COVID-19 patients. These include clinically available drugs such as chloroquine, hydroxychloroquine, and lopinavir/ritonavir. However, understanding the pathogenic mechanisms of this virus is critical for predicting interaction with humans. Based on recent evidence, we have summarized the current virus biology in terms of the possible understanding of the various pathophysiologies, molecular mechanisms, recent efficient diagnostics, and therapeutic approaches to control the disease. In addition, we briefly reviewed the biochemistry of leading candidates for novel therapies and their current status in clinical trials. As information from COVID-19 is evolving rapidly, this review will help the researcher to consider new insights and potential therapeutic approaches based on up-to-date knowledge. Finally, this review illustrates a list of alternative therapeutic solutions for a viral infection.

show abstract

“…The infection poses a significant risk to patients with COVID-19 due to the high frequency of pneumonia, fever, and dry cough. Additionally, patients suffer from the potential damage of vital organs, especially the lungs, heart, liver, and kidneys [ [8] , [9] , [10] ]. As per the latest reports from China, the mortality rate of COVID-19 disease is approximately 3–4% [ 11 ].…”

mentioning

confidence: 99%

Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19)

et al. 2020

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a major public health concern currently. To date, there are no approved antiviral drugs or vaccines against this transmissible disease. This report sheds light on available information for a better understanding of clinical trials and pharmacotherapy related to COVID-19. MEDLINE, PubMed, EMBASE, Scopus databases, Web of Science, WHO, and EU clinical trial sites were used to perform comparative analysis. Information was collected on the use of therapeutic agents for human therapy in patients with COVID-19 up to May 2020. We have extracted data from 60 clinical trials. Amongst these trials, 34 were from the European Union database of clinical trials and 26 from the National Institute of Health. The data selection procedure includes active, completed, and recruitment in progress status. Most of the clinical trials are ongoing and hence, there is a lack of precise results for the treatment.There is a lack of high-quality clinical evidence. The protocol to be developed requires large randomized clinical trials with a combination of available drugs and prospective therapies. We propose the usage of a large number of cases and different statistical analyses to conduct systematic clinical trials. This could provide comprehensive information about the clinical trial and potential therapeutic progress.

show abstract

The Fuzzy Connection between SARS-CoV-2 Infection and Loss of Renal Function

Cited by 4 publications

References 10 publications

Predicting Transmissibility-Increasing Coronavirus (SARS-CoV-2) Mutations

Predicting Transmissibility-Increasing Coronavirus (SARS-CoV-2) Mutations

Molecular mechanism, diagnosis, and potential treatment for novel coronavirus (COVID-19): a current literature review and perspective

Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19)

Contact Info

Product

Resources

About